Neurocrine Biosciences (NBIX) reported $687.5 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 16.5%. EPS of $1.06 for the same period compares to $0.63 a year ago.
The reported revenue represents a surprise of +5.72% over the Zacks Consensus Estimate of $650.3 million. With the consensus EPS estimate being $0.98, the EPS surprise was +8.16%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Neurocrine performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:- Revenues- Product sales, net: $682 million versus $635.87 million estimated by 10 analysts on average. Compared to the year-ago quarter, this number represents a +16.8% change.
- Revenues- Collaboration revenue: $5.5 million versus the 10-analyst average estimate of $6.04 million. The reported number represents a year-over-year change of -14.1%.
- Revenues- Product sales, net- INGREZZA: $624.4 million versus the nine-analyst average estimate of $620.8 million. The reported number represents a year-over-year change of +7.8%.
- Revenues- Product sales, net- CRENESSITY: $53.2 million compared to the $19.82 million average estimate based on eight analysts.
- Revenues- Product sales, net- Other: $4.4 million versus $4 million estimated by two analysts on average.
- Revenues- Collaboration revenue- Royalty: $5.1 million versus $5.35 million estimated by two analysts on average.
View all Key Company Metrics for Neurocrine here>>>
Shares of Neurocrine have returned +4.8% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.#1 Semiconductor Stock to Buy (Not NVDA)
The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow.
One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be.
See This Stock Now for Free >>Neurocrine Biosciences, Inc. (NBIX) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
